 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
3 News |  |
- CT-1530 / Centaurus Biopharma
Hybrid erbium(III)–bacteriochlorin near-infrared probes for multiplexed biomedical imaging (Virtual-only (Zoom)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_6362;
(g) Preparation of the CT1530 and through-skull intravital microscopic imaging of cancer metastasis. (h) Schematic illustration showing the protocol of NIR-II intravital microscopic imaging (i) Dual pseudo-color images of the cancer cells (red) and the blood vessels (green), performed by using emission-multiplexed method.
- |||| CT-1530 / Centaurus Biopharma
Enrollment open: Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Jul 19, 2017
P1/2, N=200, Recruiting, Sponsor: Centaurus Biopharma Co., Ltd.
(h) Schematic illustration showing the protocol of NIR-II intravital microscopic imaging (i) Dual pseudo-color images of the cancer cells (red) and the blood vessels (green), performed by using emission-multiplexed method. Not yet recruiting --> Recruiting
- ||| CT-1530 / Centaurus Biopharma
Trial initiation date: Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Mar 10, 2017
P1/2, N=200, Not yet recruiting, Sponsor: Centaurus Biopharma Co., Ltd.
Not yet recruiting --> Recruiting Initiation date: Dec 2016 --> Apr 2017
- ||||| CT-1530 / Centaurus Biopharma
New P1/2 trial: Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Dec 4, 2016
P1/2, N=200, Not yet recruiting, Sponsor: Centaurus Biopharma Co., Ltd.